Ovarian cancer
Conditions
Interventions
Index test:Hematoxylin and Eosin (H&E) staining in pathology,Whole Slide Imaging,Homologous Recombination Deficiency (HRD) detected by genomic sequencing
Sponsors
The International Peace Maternity and Child Health Hospital of the China Welfare Institute
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1,Patients with high-grade serous ovarian cancer (HGSOC) confirmed by histopathology. 2,Availability of tumor tissue paraffin blocks suitable for scanning or whole-slide image (WSI) data meeting quality requirements. 3,Completion of clinical data collection, including age, FIGO stage, surgical details, chemotherapy regimen and other relevant information. 4,(For the retrospective cohort) Known genomic testing results of homologous recombination deficiency (HRD) and/or administration of PARP inhibitors with clear follow-up records of therapeutic response.
Exclusion criteria
Exclusion criteria: 1,Insufficient quantity or poor quality of pathological tissue precluding digital analysis. 2,Severe deficiency of clinical or follow-up data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Homologous Recombination Deficiency; | — |
Countries
China
Contacts
Public ContactWang Yudong
The International Peace Maternity and Child Health Hospital of the China Welfare Institute
Outcome results
None listed